You just read:

Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome

News provided by

Neurocrine Biosciences, Inc.

Jul 28, 2016, 16:02 ET